Edgar Filing: ATRIX LABORATORIES INC - Form 8-K

ATRIX LABORATORIES INC Form 8-K October 17, 2001

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 15, 2001

(Date of earliest event reported)

ATRIX LABORATORIES, INC.

(Exact name of Registrant as specified in its charter)

2579 Midpoint Drive, Fort Collins, Colorado 80525
-----(Address of principal executive offices, including zip code)

(970) 482-5868

(Registrant's telephone number, including area code)

Item 5. Other Events.

On October 15, 2001, Atrix Laboratories, Inc. (the "Company") entered into a Collaboration, License and Supply Agreement with Fujisawa Healthcare, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. ("Fujisawa"), under which the Company granted Fujisawa the exclusive North American marketing and distribution rights for the Company's proprietary dermatological product, Atrisone(TM) dapsone topical gel. Under the terms of the agreement, the Company will receive up to \$25 million in licensing fees, research and development support, and milestone payments. The Company will also receive royalties based on North American sales of the products. As part of the Agreement, the Company will manufacture the product for Fujisawa and receive a manufacturing margin.

The text of the press release announcing the transaction is attached hereto as Exhibit 99.1.

Edgar Filing: ATRIX LABORATORIES INC - Form 8-K

Item 7. Exhibits.

99.1 Press Release dated as of October 17, 2001

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRIX LABORATORIES, INC.

By: /s/ BRIAN G. RICHMOND

.

Brian G. Richmond Chief Financial Officer

Date: October 17, 2001

EXHIBIT INDEX

EXHIBIT DESCRIPTION

99.1 Press Release dated as of October 17, 2001